Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
amlodipine + chlorthalidone + valsartan
- Development stage
- Phase 3
- Lead developer
- AJU Pharm
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
AJU-C52H is a fixed-dose combination drug containing amlodipine (a calcium channel blocker), chlorthalidone (a thiazide-like diuretic), and valsartan (an angiotensin II receptor antagonist). It is being developed by Aju Pharm for the treatment of essential hypertension. The combination targets multiple mechanisms involved in blood pressure regulation to provide enhanced antihypertensive efficacy. Clinical trials have reached Phase 3 in South Korea for patients with essential hypertension who are inadequately controlled on other therapies[1][2][6].
- Other names
- AJU C52HAJU C52LAJU C52
02
Targets
AGTR1 (Angiotensin II Type-1 receptor)LTCC (Voltage-gated calcium channel (L-type))SLC12A3 (Thiazide-sensitive sodium-chloride cotransporter)
Beyond the preview
Go deeper on amlodipine + chlorthalidone + valsartan.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on amlodipine + chlorthalidone + valsartan.